12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)

12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)

[!NOTE] Clinical Competency Core: Maximizing lipid-lowering therapy frequently encounters statin-associated muscle symptoms (SAMS) and the need for non-statin pharmacotherapy to achieve strict secondary prevention goals. Cardiac rehabilitation professionals must distinguish subjective myalgia from true toxic myopathy, execute structured drug re-challenge protocols, and understand the pharmacology and trial evidence of ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran, and icosapent ethyl.

While statins remain first-line therapy for secondary prevention, real-world clinical practice reveals two major hurdles: statin intolerance and insufficient LDL-C reduction on statin monotherapy. Approximately 10% of cardiac patients report musculoskeletal side effects that threaten adherence, while patients categorized as very high-risk ASCVD frequently fail to reach the stringent <55 mg/dL threshold without combination therapy. Successfully navigating SAMS and integrating non-statin pharmacotherapies is essential for reducing recurrent atherothrombotic events.

---

Statin-Associated Muscle Symptoms (SAMS): Phenotypes, Diagnosis & Management

Statin-associated muscle symptoms represent the most frequent reason for statin non-adherence and discontinuation in cardiac rehabilitation. SAMS spans a distinct clinical and biochemical spectrum:

The Nocebo / Drucebo Effect in SAMS

Although observational registries report muscle complaints in 10% to 20% of statin-treated patients, large blinded, placebo-controlled randomized clinical trials (such as the GAUSS-3 and SAMSON trials) reveal that over 75% to 80% of muscle symptoms are driven by the nocebo effect (anticipation of negative side effects). When patients are randomized blindly between statin, placebo, and empty tablets, muscle symptom scores on placebo closely match those on active statins.

Predisposing Risk Factors & Drug Interactions

Clinicians must assess secondary vulnerabilities before declaring a patient statin-intolerant:

• Endocrine and Metabolic: Unrecognized hypothyroidism (elevated TSH downregulates hepatic LDLR and impairs skeletal muscle mitochondrial oxidative phosphorylation, dramatically increasing statin myotoxicity risk) and severe vitamin D deficiency (<20 ng/mL).
• Patient Characteristics: Advanced age (>75 years), female sex, low body mass index (BMI <18.5 kg/m²), renal insufficiency, and heavy alcohol intake.
• CYP3A4 Pharmacokinetic Interactions: Lipophilic statins (atorvastatin, simvastatin, lovastatin) undergo hepatic metabolism via the cytochrome P450 3A4 isozyme. Co-administration of potent CYP3A4 inhibitors—including macrolide antibiotics (clarithromycin, erythromycin), azole antifungals (ketoconazole, itraconazole), non-dihydropyridine CCBs (diltiazem, verapamil), amiodarone, HIV protease inhibitors, and large volumes of grapefruit juice (>1 quart daily)—dramatically elevates systemic statin concentrations.
• Gemfibrozil Contraindication: Gemfibrozil competitively inhibits the glucuronidation of statin hydroxy acids and impairs hepatic OATP1B1 uptake, multiplying statin area-under-the-curve (AUC) by several fold. Gemfibrozil is strictly contraindicated with statins; fenofibrate is the preferred fibrate if triglyceride management requires adjunctive therapy.

Structured SAMS Management Algorithm

1. Obtain Baseline Laboratory Testing: Draw serum CK, TSH, and renal panel to confirm myalgia vs myopathy and exclude hypothyroidism.
2. Initiate a Statin Holiday: Discontinue the statin for 2 to 4 weeks. If muscle aches fail to resolve during the drug holiday, the symptoms are unrelated to statin therapy.
3. Transition from Lipophilic to Hydrophilic Statins: Lipophilic agents (atorvastatin, simvastatin, lovastatin) enter non-hepatic tissues via passive membrane diffusion. In contrast, hydrophilic statins (rosuvastatin and pravastatin) are hepatoselective; their cellular uptake requires the liver-specific Organic Anion Transporting Polypeptide 1B1 (OATP1B1), dramatically minimizing off-target passive penetration into skeletal myocytes.
4. Alternate-Day or Non-Daily Dosing: Because rosuvastatin (half-life $\approx 19$ hours) and atorvastatin (half-life $\approx 14$ hours) possess extended half-lives, dosing 2 to 3 times weekly (e.g., rosuvastatin 5 to 10 mg on Monday, Wednesday, Friday) achieves 60% to 75% of daily lipid-lowering efficacy while remaining symptom-free.

---

Ezetimibe: Mechanism, Efficacy & Evidence

Ezetimibe is the established first-line non-statin agent in secondary prevention.

• Mechanism of Action: Ezetimibe selectively targets and binds the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter protein on the brush border membrane of jejunal enterocytes. By blocking the active internalization of dietary and biliary cholesterol without inhibiting the absorption of triglycerides, bile acids, or fat-soluble vitamins, ezetimibe reduces cholesterol transport to the liver. Depleted hepatic cholesterol stores upregulate cell-surface hepatic LDL receptors, accelerating LDL clearance from systemic circulation.
• Efficacy: Monotherapy lowers LDL-C by 15% to 18%; added to a statin, it provides an incremental 15% to 20% reduction in LDL-C and a 10% to 15% reduction in ApoB.
• The IMPROVE-IT Trial: In 18,144 post-ACS patients, adding ezetimibe 10 mg to simvastatin 40 mg lowered median LDL-C from 69.5 mg/dL to 53.7 mg/dL, yielding a significant reduction in cardiovascular death, MI, and stroke (hazard ratio 0.936, p=0.016). This trial confirmed the clinical principle that lowering LDL-C confers cardiovascular protection regardless of the pharmacological mechanism.

---

PCSK9 Inhibitors: Monoclonal Antibodies

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a serine protease secreted by hepatocytes that binds to cell-surface LDL receptors, promoting their lysosomal internalization and destruction rather than their recycling to the membrane.

• Mechanism of Action: Evolocumab and Alirocumab are fully human monoclonal antibodies (mAbs) that bind circulating PCSK9 with high affinity, preventing PCSK9-mediated LDLR degradation. Hepatic LDL receptors cycle back to the cell surface up to 150 times, dramatically enhancing plasma clearance of LDL, VLDL remnants, and Lp(a).
• Efficacy: Lowers LDL-C by 50% to 60% beyond statin therapy, decreases ApoB by 40% to 50%, and lowers Lipoprotein(a) by 20% to 30%.
• Trial Evidence:
  • FOURIER (Evolocumab): Enrolled 27,564 stable ASCVD patients on statin therapy. Evolocumab reduced median LDL-C to 30 mg/dL and reduced MACE by 15% (p<0.001) without neurocognitive or muscular toxicities.
  • ODYSSEY OUTCOMES (Alirocumab): Enrolled 18,924 post-ACS patients, demonstrating significant MACE reductions and a reduction in all-cause mortality among high-risk patients with baseline LDL-C ≥100 mg/dL.
• Dosing: Administered via subcutaneous autoinjector every 2 weeks or monthly.

---

Novel and Emerging Pharmacotherapies

• Bempedoic Acid (Nexletol):
  • Mechanism: An oral prodrug that inhibits ATP-citrate lyase (ACL), an essential cytosolic enzyme acting two steps upstream of HMG-CoA reductase in hepatic cholesterol synthesis. Crucially, bempedoic acid requires conversion to bempedoyl-CoA by the enzyme very long-chain acyl-CoA synthetase-1 (ACSVL1). Because ACSVL1 is highly expressed in hepatocytes but absent in skeletal muscle, bempedoic acid cannot be activated in myocytes and produces zero statin-like skeletal muscle toxicity.
  • Efficacy & Trial: Lowers LDL-C by 15% to 25% (or ~38% when co-formulated with ezetimibe). The CLEAR Outcomes trial in 13,970 statin-intolerant patients proved a significant 13% reduction in major adverse cardiovascular events.
• Inclisiran (Leqvio):
  • Mechanism: A synthetic small interfering RNA (siRNA) conjugated with triantennary N-acetylgalactosamine (GalNAc) carbohydrates that bind specifically to asialoglycoprotein receptors on hepatocytes. Once inside the hepatocyte, inclisiran engages the RNA-induced silencing complex (RISC) to cleave PCSK9 mRNA, preventing PCSK9 protein translation.
  • Dosing & Efficacy: Administered subcutaneously by a healthcare professional at baseline, 3 months, and then every 6 months. Produces sustained, durable ~50% reductions in LDL-C with guaranteed adherence.
• Icosapent Ethyl (Vascepa):
  • Mechanism: A highly purified ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA) that excludes docosahexaenoic acid (DHA). Unlike mixed fish oils (where DHA raises LDL-C), icosapent ethyl stabilizes endothelial membranes, reduces lipid peroxidation, and inhibits platelet aggregation without increasing LDL-C.
  • REDUCE-IT Trial: In 8,179 statin-treated patients with established ASCVD or diabetes plus risk factors with elevated fasting triglycerides (135–499 mg/dL), icosapent ethyl 4 g/day produced a landmark 25% relative risk reduction in MACE (p<0.0001).

---

Clinical Case Scenario: Statin Intolerance Management & Multi-Pathway Success

Clinical Presentation: A 65-year-old male post-CABG reports debilitating bilateral thigh weakness and pain 3 weeks after starting atorvastatin 40 mg. Creatine kinase is mildly elevated at 280 U/L (reference range 30–170 U/L); serum TSH and creatinine are normal.

Multidisciplinary Management:

1. Statin Holiday: Atorvastatin is held for 3 weeks; muscle pain completely resolves and CK normalizes to 110 U/L.
2. Hydrophilic Rechallenge: He is initiated on low-dose rosuvastatin 5 mg every other day. Because rosuvastatin is hydrophilic and excluded from myocytes lacking OATP1B1, he remains asymptomatic.
3. Therapeutic Combination: Because low-dose alternate-day rosuvastatin only lowers his LDL from 138 to 98 mg/dL (far above the <55 mg/dL target), the team adds oral ezetimibe 10 mg daily (reducing LDL to 78 mg/dL) and bempedoic acid 180 mg daily (providing ACL inhibition without muscle exposure).
4. Clinical Outcome: His repeat LDL-C drops to 48 mg/dL. He successfully participates in Phase II exercise training without muscle pain, demonstrating that multi-pathway non-statin regimens achieve strict secondary prevention goals in patients with partial statin intolerance.